00:53 , Mar 17, 2015 |  BC Extra  |  Company News

Management tracks

Oral therapies developer Chiasma Inc. (Jerusalem, Israel) named Mark Leuchtenberger president and CEO. Leuchtenberger was president and CEO of Acusphere Inc. (Pink:ACUS). Leuchtenberger succeeds Roni Mamluk, whom Chiasma named chief development officer. mRNA technology company...
08:00 , Dec 8, 2014 |  BC Week In Review  |  Clinical News

MecA XpressFISH test regulatory update

FDA granted 510(k) clearance for the mecA XpressFISH test from AdvanDx to detect mecA mRNA from methicillin-resistant Staphylococcus aureus from blood cultures positive for S. aureus. The qualitative fluorescence in situ hybridization (FISH) assay uses...
07:00 , Apr 14, 2014 |  BC Week In Review  |  Financial News

AdvanDx completes venture financing

AdvanDx Inc., Woburn, Mass.   Business: Diagnostic   Date completed: 4/8/14   Type: Venture financing   Raised: $9 million   Investors: Merck Global Health Innovation Fund; SLS Invest; LD Pension Fund   Note: The company raised $9 million from a secured...
00:22 , Apr 9, 2014 |  BC Extra  |  Financial News

AdvanDx secures $12 million in B-1 round

Molecular diagnostics company AdvanDx Inc. (Woburn, Mass.) raised $9 million in a $12 million series B-1 round led by new investor Merck Global Health Innovation Fund. Existing investors SLS Ventures and LD Pensions also participated....
07:00 , Mar 24, 2014 |  BC Week In Review  |  Clinical News

MecA XpressFISH test regulatory update

AdvanDx submitted a 510(k) application to FDA for its mecA XpressFISH test to rapidly detect methicillin-resistant Staphylococcus aureus (MRSA) from blood cultures positive for S. aureus. The qualitative fluorescence in situ hybridization (FISH) assay uses...
07:00 , Sep 17, 2012 |  BC Week In Review  |  Company News

AdvanDx sales and marketing update

AdvanDx will launch the QuickFISH 20 Min. Pathogen ID test in the U.S. and EU on Sept. 24 to identify pathogens, including Staphylococcus aureus and coagulase-negative staphylococci that cause bloodstream infections. The molecular...
08:00 , Jan 24, 2011 |  BC Week In Review  |  Clinical News

GNR Traffic Light PNA FISH regulatory update

FDA granted 510(k) clearance for AdvanDx's GNR Traffic Light PNA FISH assay for the simultaneous identification of Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa from positive blood cultures in less than 90 minutes. AdvanDx will...
07:00 , Aug 16, 2010 |  BC Week In Review  |  Company News

AdvanDx sales and marketing update

AdvanDx launched its GNR Traffic Light PNA FISH in Europe to simultaneously identify Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa directly from positive blood cultures in less than 90 minutes. Pricing information was not disclosed....
07:00 , Aug 9, 2010 |  BC Week In Review  |  Clinical News

Yeast Traffic Light PNA FISH regulatory update

FDA granted 510(k) clearance for a 90-minute protocol for AdvanDx's Yeast Traffic Light PNA FISH to identify Candida species from blood cultures. bioMerieux S.A. (Euronext:BIM, Marcy l'Etoile, France) has U.S. marketing rights to the...
07:00 , May 31, 2010 |  BC Week In Review  |  Company News

AdvanDx, Inverness sales and marketing update

AdvanDx launched the BinaxNOW PBP2a test in the U.S. to identify methicillin-resistant Staphylococcus aureus (MRSA). The test detects the penicillin-binding protein (PBP) 2a in blood samples that have tested positive for S. aureus. AdvanDx has...